Endonovo Therapeutics (ENDV) AI Stock Analysis

• Market Cap: $180.76K
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): 202.74
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,807,556,300
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: <0.01
• Price to Book (P/B): >-0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: 38.33
• Enterprise Value/Revenue: 689.80
• Enterprise Value/Gross Profit: -11.26
• Enterprise Value/Ebitda: -7.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: ― N/A
• Price Target: ―
• Action: N/A
• Date: ―

Positive Factors

Innovative Product Offering

Endonovo's focus on non-invasive, bioelectronic therapies positions it well in the growing field of regenerative medicine, offering a unique solution for pain management and recovery.

Negative Factors

Financial Instability

Negative equity and high liabilities indicate financial distress, posing risks to long-term viability and limiting strategic options.

Endonovo Therapeutics Business Overview & Revenue Model

Company Description

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering i...

Read more

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering i...

How the Company Makes Money

Endonovo Therapeutics primarily generates revenue through the sale and lease of its SofPulse devices to hospitals, clinics, and other healthcare facilities. The company's revenue model includes direct sales, leasing arrangements, and service agree...

Read more

Endonovo Therapeutics primarily generates revenue through the sale and lease of its SofPulse devices to hospitals, clinics, and other healthcare facilities. The company's revenue model includes direct sales, leasing arrangements, and service agree...

Endonovo Therapeutics Financial Statement Overview

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Mar 2022
Income Statement
Total Revenue	10.04K	0.00	10.04K	140.24K	135.35K	73.11K
Gross Profit	-615.20K	0.00	-615.20K	-514.51K	125.36K	58.12K
EBITDA	-941.40K	-945.77K	-941.40K	8.85M	-16.51M	-1.51M
Net Income	-2.80M	-2.18M	-2.80M	6.92M	-18.47M	-3.10M
Balance Sheet
Total Assets	19.29K	19.30K	19.29K	639.66K	1.28M	2.01M
Cash, Cash Equivalents and Short-Term Investments	3.00	12.00	3.00	1.84K	98.00	85.94K
Total Debt	6.87M	6.91M	6.87M	7.07M	7.15M	7.18M
Total Liabilities	26.82M	28.89M	26.82M	24.75M	33.46M	17.78M
Stockholders Equity	-26.80M	-28.87M	-26.80M	-24.11M	-32.18M	-15.77M
Cash Flow
Free Cash Flow	100.48K	-42.99K	100.49K	121.87K	-678.84K	-986.58K
Operating Cash Flow	100.49K	-42.99K	100.49K	121.87K	-678.84K	-986.58K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	-105.33K	43.00K	-105.33K	-120.13K	593.00K	1.06M

Endonovo Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENDV	―	$180.76K	-0.06	―	―	―	―
SCNI	45 Neutral	$1.17M	―	―	―	-1.81%	-217.37%
DRMA	45 Neutral	$4.75M	-0.64	-203.36%	―	―	93.30%
BJDX	44 Neutral	$5.06M	-0.32	-145.52%	―	―	98.81%
NUWE	43 Neutral	$1.82M	-0.02	-6046.59%	―	-0.20%	91.63%
PRFX	43 Neutral	$1.18M	-0.04	―	―	―	―